Current and future use of heor data in healthcare decision-making in the united states and in emerging markets

American Health and Drug Benefits

Volumn 5, Issue 7, 2012, Pages

  Holtorf, Anke Peggy ^a   Brixner, Diana ^b   Bellows, Brandon ^b   Keskinaslan, Abdulkadir ^c   Dye, Joseph ^d   Oderda, Gary ^b,e  

^a Health Outcomes Strategies   (Switzerland)

^b UNIVERSITY OF UTAH   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Novartis Pharma AG ^*  (United States)

^e Utah Medicaid Drug Regimen Review Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCESS TO INFORMATION; AFRICA; ARTICLE; COST BENEFIT ANALYSIS; DECISION MAKING; DRUG CHOICE; DRUG COST; DRUG MARKETING; DRUG SAFETY; HEALTH CARE POLICY; HEALTH CARE SURVEY; HUMAN; MANAGED CARE; MEDICAL INFORMATICS; MIDDLE EAST; OUTCOME ASSESSMENT; PILOT STUDY; QUALITY CONTROL; REIMBURSEMENT; SOUTH AND CENTRAL AMERICA; UNITED STATES;

EID: 84871561965     PISSN: 19422962     EISSN: 19422970     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Garrison LP Jr, Neumann PJ, Radensky P, Walcoff SD. A flexible approach to evidentiary standards for comparative effectiveness research. Health Aff (Millwood). 2010;29:1812-1817.
2. Chambers JD, Neumann PJ. US healthcare reform: implications for health economics and outcomes research. Expert Rev Pharmacoecon Outcomes Res. 2010;10:215-216.
3. van Nooten F, Holmstrom S, Green J, et al. Health economics and outcomes research within drug development: challenges and opportunities for reimbursement and market access within biopharma research. Drug Discov Today. 2012;17:615-622.
4. Doherty J, Kamae I, Lee KK, et al. What is next for pharmacoeconomics and outcomes research in Asia? Value Health. 2004;7:118-132.
5. Tantivess S, Teerawattananon Y, Mills A. Strengthening cost-effectiveness analysis in Thailand through the establishment of the health intervention and technology assessment program. Pharmacoeconomics. 2009;27:931-945.
6. Holtorf AP, Watkins JB, Mullins CD, Brixner D. Incorporating observational data into the formulary decision-making process-summary of a roundtable discussion. J Manag Care Pharm. 2008;14:302-308.
7. Brixner DI, Holtorf AP, Neumann PJ, et al. Standardizing quality assessment of observational studies for decision making in health care. J Manag Care Pharm. 2009; 15:275-283.
8. Biskupiak J, Brixner DI, Holtorf AP. Current and future use of pharmacoeconomic and pharmacotherapy outcomes research data in decision making. Abstract presented at the 12th Biennial European Meeting of the Society for Medical Decision Making; May 30-June 2, 2010; Hall/Innsbruck, Austria. Abstract 22.
9. Leung MY, Halpern MT, West ND. Pharmaceutical technology assessment: perspectives from payers. J Manag Care Pharm. 2012;18:256-264.
10. Gallio D, Berto P. Health technology assessment (HTA): definition, role and use in the changing healthcare environment. Eur Ann Allergy Clin Immunol. 2007;39 Spec No:7-11.
11. Rasooldeen R. Move under way to set up pharmacoeconomics center. April 29, 2012. www.arabnews.com/node/412095. Accessed November 13, 2012.